Stock Price & Analysis

Based on the provided data and recent market activity, here's my analysis for STVN:

Technical Analysis

The stock is showing significant weakness, currently trading at $19.54, down 10.33% YTD and -41.46% over the past year. The stock has broken below several key support levels and is exhibiting bearish momentum with RSI at 30.15, indicating oversold conditions but still lacking clear reversal signals.

Recent Events & Price Catalysts

• The stock experienced a sharp decline of 5.8% in recent trading, with volume significantly higher than average at 550,561 shares compared to the 368,547 average volume.
• The company recently announced a major public offering of ordinary shares, which typically puts downward pressure on stock price due to dilution concerns.

Fundamental Analysis

Key Metrics:

• P/E Ratio: 43.42x (indicating relatively expensive valuation)
• Market Cap: $5.33B
• Beta: 0.56 (lower volatility than market)

Analyst Sentiment

• Wall Street consensus shows a "Moderate Buy" rating
• Average price target of $25.67, suggesting a potential upside of 31.36%
• Price targets range from $23.00 to $28.00

Recommendation Given the current technical weakness and high valuation multiples, despite analyst optimism, it would be prudent to SELL STVN at current levels. Key factors supporting this recommendation:

1. Negative technical momentum and broken support levels
2. High P/E ratio relative to market average
3. Recent equity offering announcement creating potential selling pressure
4. Significant YTD and 1-year underperformance

Consider re-evaluating entry positions if the stock shows clear technical reversal signals or reaches the $16.50-$17.00 support zone.

Based on the provided data and current market conditions, here's a detailed analysis for STVN's price prediction in 2025:

Technical Analysis

The stock is currently showing bearish momentum with key technical indicators:

• RSI-14 at 36.97 indicates oversold conditions
• MACD is negative at -0.52 with bearish divergence
• Stock trading below both 5-day (20.00) and 10-day (21.11) moving averages

Price Targets Based on Technical Levels

The Fibonacci analysis suggests:

• Strong resistance at $22.52 (R1)
• Key support at $19.06 (S1)
• Current price ($19.54) is testing the S1 support level

Recent News Impact

According to recent news, STVN experienced significant pre-market declines, falling 16.1% to $16.01 after a 5% decline in the previous session, indicating strong selling pressure.

2025 Price Prediction

Based on technical analysis, fundamental indicators, and current market sentiment, STVN is expected to trade in the range of $23-25 by end of 2025, representing a potential upside of 15-25% from current levels. This projection is supported by:

• Strong support at $19.06 level providing downside protection
• Technical indicators suggesting oversold conditions
• Historical price patterns showing potential for mean reversion

The probability of reaching this target depends on:

• Market sentiment improvement
• Company's ability to maintain growth momentum
• Overall market conditions in the healthcare sector

Note: This prediction is based on technical analysis and available data. Market conditions can change rapidly, and past performance does not guarantee future results. Investors should conduct their own research and consider their risk tolerance before making investment decisions.

The S1 support level for STVN Stock is $18.82 ,The R1 resistant level for STVN Stock is $22.28.

As of the end of day on 2025-02-21, the price of STVN Stock was $20.9.

The target price for STVN Stock according to analyst rating is 25.67, with the highest price target at 28.00 and the lowest at 23.00. Analysts have a Moderate Buy rating on STVN Stock overall.

The market cap of STVN is $6.3B.

Based on the provided data and recent market activity, here's a comprehensive analysis of STVN's valuation:

Current Market Position STVN is currently trading at $19.54, down 38.3% over the past year. The stock has shown significant volatility recently, with a 15% decline reported on February 13th.

Valuation Analysis The stock appears fairly valued based on several metrics:

1. Growth and Margins:

• Revenue growth showing strong momentum (Q3 2024: $277.9M, up from Q1: $236M)
• Improving profit margins (Net margin increased from 7.97% to 10.8% in Q3 2024)
• Healthy gross margins around 28%

2. Financial Health:

• Strong current ratio of 1.81 (Q3 2024)
• Reasonable debt-to-equity of 27.36%
• Solid cash position and improving operational metrics

Analyst Perspectives Recent analyst coverage indicates mixed views:

• Wolfe Research: Buy rating with $28 target (20.12% upside)
• B of A Securities: Strong Buy with $26 target (11.54% upside)
• Morgan Stanley: Hold rating with $23 target (14.6% upside)

Key Findings STVN is not overvalued when considering:

• Strong revenue growth trajectory
• Improving profitability metrics
• Healthy balance sheet
• Positive analyst sentiment with price targets above current trading levels
• Market position in biopharmaceutical injectables with structural growth drivers

The recent stock decline appears more related to market sentiment than fundamental deterioration, suggesting current prices may represent a reasonable entry point for long-term investors.

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.

Based on the provided data and market context, here's a price prediction analysis for STVN stock by 2030:

STVN stock is projected to reach $32-35 by 2030, driven by strong healthcare sector growth and aging population demographics. The healthcare and social assistance sector is expected to add 3.3 million jobs through 2030, which should benefit Stevanato Group's medical technology and drug containment solutions business.

Recent stock performance shows volatility between $16-34 range, with current trading around $19.54, suggesting significant upside potential as the company capitalizes on healthcare industry expansion and increased demand for specialized medical packaging solutions.

Note: This prediction is based on current market conditions and available data. Actual future prices may vary significantly due to unforeseen market events, company performance, or economic conditions.

STVN has a total of 5635 employees.